12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Company News  |  Deals

Algorithm, Iroko, Fahrenheit deal

Iroko granted Algorithm exclusive rights to develop and commercialize Zorvolex submicron diclofenac in the Middle East and North Africa (MENA) region. Separately, Iroko granted Fahrenheit exclusive rights to develop...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >